DRUG RESISTANCE

Three- dimensional (3D) Cancer Microenvironment that Confers Chemoresistance to DNA Damaging Drug

Targeted Delivery of NVPBEZ235 conjugated to gold nanoparticles for Overcoming Gemcitabine Resistance in Triple-Negative Breast Cancer

In Silico Identification of Common Pre-existing Resistance Mechanisms to EGFR Inhibitors in Colorectal Cancer

Overcoming paclitaxel resistance in ovarian cancer cells using DN200434, an inverse agonist of Estrogen-related receptor gamma (ERRγ)

A newly discovered mTOR-STAT3 pathway regulates calcium release and calcium-mediated apoptosis at the ER in Triple Negative Breast Cancer

Evaluate the potential sensitization effect and underlying mechanism of tyrosine kinase inhibitor on cisplatin resistance oral squamous cell carcinoma

Study of long non-coding RNAs in resistance to KRAS G12C inhibitors in lung cancers

Targeting the Non-Homologous End-Joining Pathway Sensitizes MDM2-Amplified Liposarcoma to Doxorubicin-Induced Senescence in a p53-dependent Manner

Regulation of FOXK2 by AKT in breast cancer cells: Serine 398 as a novel potential phosphorylation site

FOXK2 transcription factor in cancer: expression, function and potential as a biomarker

Targeting low fidelity polymerases to prevent acquired resistance mutations to EGFR-targeted therapy in lung cancer.

Inhibition of the extracellular signal-regulated kinase 5 (ERK5) increases EGFR expression and its nuclear localization in HCC, generating new targeting opportunities

mTORC1 Fuels Resistance but Unlocks Metabolic Kill-Switch in PI3K-Mutant Breast Cancer

Assessment of two new ROS1+ NSCLC patient-derived cell lines as in vitro models for TKI resistance studies

Discovery of Molecular and Epigenetic Candidates Underlying Chemoresistance of Colorectal Cancer

The mechanism of PPARα-mediated cholesterol metabolism in regulating paclitaxel resistance in ovarian cancer cells

AP-1 transcription factor is a targetable mediator of osimertinib resistance in EGFR-mutant non-small cell lung cancer

Overactivation of oncogenic signaling steers cancer cells toward less malignant phenotypes

CIC: The Master Regulator of Resistance to MAPK Pathway Inhibition

Unlocking New Therapies: Targeting GSDMB Overexpression in HER2-Positive Tumors

FGFR signaling as a key mediator of resistance to alpelisib/fulvestrant combination in PIK3CA-mutant luminal A breast cancer

Investigation of the expression of drug resistance genes after Sorafenib administration

Targeting CCL19/21-CCR7 axis to overcome resistance to ALK inhibitors in ALK+ lymphoma

Genomic Instability and Epigenomic Dysregulation as Hallmarks of mCRC Therapy Resistance — Findings from Broad ctDNA Molecular Profiling (METACC)

Exploring potential strategies overcoming the PARPi resistance in the Olaparib induced MDA-MB-436 resistant model

BMI1 as a therapeutic target to overcome chemoresistance in high-grade serous ovarian cancer

Identification of microRNAs and their target genes associated with acquired resistance of primary melanoma cells to targeted therapy

Impact of Mechanical Stress and Confinement on the Alteration of Protein Expression and Emergence of Time-Dependent Resistance to Cisplatin

Uncovering Transcriptional Signatures of Differential Drug Response in Archetypical Malignant States in Metastatic Breast Cancer (MBC)

Overcoming P-glycoprotein-mediated resistance in tumor cells through copolymers for cytotoxic drug delivery

Dual targeting BRD4-CDK9 transcriptional complex as a potent therapeutic strategy in glioblastoma

Unraveling mechanisms of CDK4/6 inhibitors resistance in metastatic breast cancer

Immune infiltration is associated with favorable response to neoadjuvant chemotherapy and carboplatin in hormone receptor positive and triple negative breast cancer

Inhibition of the RNA-binding protein HuR reduces cell proliferation and promotes apoptosis in EGFR-TKI resistant NSCLC cells

Targeting PI3K/AKT Pathway Dysregulation in Triple-Negative Breast Cancer: Overcoming Alpelisib Resistance through Dual Inhibition

Endothelial-Derived CAFs Drive Chemoresistance via ERCC1-IL-17A Axis: A Novel Therapeutic Target in Tumour Microenvironment

miR-181a-5p and Caveolin-1 Express Inversely in HCC and Augment the Aggressive Phenotype of Sorafenib-Resistant HCC Cells

Overcoming Taxane Resistance Through PRMT5 Inhibition: Targeting Epigenetic Mechanisms

Unraveling tumor intrinsic responses: IFN-gamma predicts clinical immunotherapy efficacy and exclusively triggers apoptosis in solid tumors while sparing hematologic malignancies

Signaling Pathways affected by RAGE inhibition in vemurafenib treated melanoma cells

Berberine, a P-glycoprotein inhibitor, shows synergistic anti-cancer effect when combined with Dactolisib in Colorectal Carcinoma HCT116 cell lines